3089.6000 -2.10 (-0.07%)
NSE Oct 29, 2025 15:31 PM
Volume: 58,347
 

3089.60
-0.07%
ICICI Securities Limited
Dr Lal’s Pathlabs’ Q1 volume growth at 2.5% was impacted to some extent due to seasonality. Favourable test mix and traction in Swasthfit improved realisation per patient by 8.5% to INR 789 and aided gross margin expansion of 181bps YoY.
Number of FII/FPI investors increased from 358 to 391 in Sep 2025 qtr.
More from Dr. Lal Pathlabs Ltd.
Recommended